EU: Ball hires Goldman Sachs to sell 11 plants to appease antitrust regulators
US drinks can maker Ball Corp is ready to sell 11 European plants to get EU antitrust regulators to approve its $6.69 billion acquisition of Britain’s Rexam, people familiar with the matter said.
The world’s two largest beverage can makers by volume want to merge to better manage capital spending and cut costs. The European Commission, however, fears the deal would push up prices for companies and consumers.
The combined company would have 60 percent of the beverage can market in North America, 69 percent in Europe and 74 percent in Brazil, according to Morningstar analysts.
Ball is prepared to divest four factories in Germany, three in the UK, one each in Spain, France, the Netherlands and Austria, the sources said on Wednesday. Nine of the plants make cans and two of them can ends. The offer was submitted to the Commission last week.
Ball has said it is willing to sell more than $1.58 billion worth of assets to allay regulatory concerns. The company is also in discussions with antitrust authorities in the United States about assets it may have to divest in that country.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas